Ionis Pharmaceuticals Stock Price, News & Analysis (NASDAQ:IONS) $49.89 -0.11 (-0.22%) (As of 09:40 AM ET) Add Compare Share Share Today's Range$49.80▼$50.2150-Day Range$43.39▼$51.6352-Week Range$32.69▼$51.89Volume11,738 shsAverage Volume1.06 million shsMarket Capitalization$7.16 billionP/E RatioN/ADividend YieldN/APrice Target$48.23 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Ionis Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.46 Rating ScoreUpside/Downside3.3% Downside$48.23 Price TargetShort InterestBearish6.95% of Float Sold ShortDividend StrengthN/ASustainability-3.58Upright™ Environmental ScoreNews Sentiment0.82Based on 5 Articles This WeekInsider TradingSelling Shares$934,603 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.46) to ($3.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.64 out of 5 starsMedical Sector856th out of 948 stocksPharmaceutical Preparations Industry389th out of 419 stocks 2.2 Analyst's Opinion Consensus RatingIonis Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.46, and is based on 6 buy ratings, 4 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $48.23, Ionis Pharmaceuticals has a forecasted downside of 3.3% from its current price of $49.89.Amount of Analyst CoverageIonis Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.95% of the float of Ionis Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIonis Pharmaceuticals has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Ionis Pharmaceuticals has recently increased by 0.41%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldIonis Pharmaceuticals does not currently pay a dividend.Dividend GrowthIonis Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIonis Pharmaceuticals has received a 27.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Neuromuscular disorders medication" product. See details.Environmental SustainabilityThe Environmental Impact score for Ionis Pharmaceuticals is -3.58. Previous Next 3.2 News and Social Media Coverage News SentimentIonis Pharmaceuticals has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Ionis Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest15 people have searched for IONS on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Ionis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ionis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $934,603.00 in company stock.Percentage Held by InsidersOnly 2.65% of the stock of Ionis Pharmaceuticals is held by insiders.Percentage Held by Institutions93.86% of the stock of Ionis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Ionis Pharmaceuticals are expected to decrease in the coming year, from ($3.46) to ($3.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ionis Pharmaceuticals is -17.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ionis Pharmaceuticals is -17.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIonis Pharmaceuticals has a P/B Ratio of 12.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ionis Pharmaceuticals Stock (NASDAQ:IONS)Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California.Read More IONS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IONS Stock News HeadlinesDecember 5, 2023 | americanbankingnews.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Recommendation of "Hold" by AnalystsDecember 4, 2023 | seekingalpha.comIonis Pharmaceuticals: Pioneering Precision MedicineDecember 6, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.December 1, 2023 | finance.yahoo.comIonis Pharmaceuticals (NASDAQ:IONS) shareholders have earned a 23% return over the last yearNovember 16, 2023 | finance.yahoo.comPraxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental EpilepsiesNovember 15, 2023 | markets.businessinsider.comPromising Trial Results and Positive EEG Activity Bolster Buy Rating for Ionis PharmaceuticalsNovember 13, 2023 | finance.yahoo.comIonis (IONS) Early-Stage Genetic Disorder Data Shows PromiseNovember 13, 2023 | msn.comIonis says Angelman syndrome drug well tolerated in studyDecember 6, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 11, 2023 | finance.yahoo.comIonis shares positive clinical update from ongoing trial of ION582 for Angelman syndromeNovember 11, 2023 | markets.businessinsider.comPromising Phase II Trial Results and Market Potential Propel Buy Rating for Ionis PharmaceuticalsNovember 9, 2023 | finance.yahoo.comIonis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedemaNovember 6, 2023 | markets.businessinsider.comHold Rating for Ionis Pharmaceuticals Following 3Q23 Results, Pipeline Updates, and Financial Performance AnalysisNovember 6, 2023 | markets.businessinsider.comSell Rating on Ionis Pharmaceuticals: An Analysis of 3Q23 Performance and Forward Outlook Despite Promising Pipeline DevelopmentsNovember 4, 2023 | finance.yahoo.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Q3 2023 Earnings Call TranscriptNovember 4, 2023 | finance.yahoo.comIs Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Trading At A 29% Discount?November 2, 2023 | seekingalpha.comIonis Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call PresentationNovember 2, 2023 | finance.yahoo.comIonis Pharmaceuticals (IONS) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesNovember 2, 2023 | finance.yahoo.comIonis Pharmaceuticals Inc (IONS) Reports Q3 2023 Financial ResultsNovember 2, 2023 | finance.yahoo.comIonis reports third quarter 2023 financial resultsOctober 19, 2023 | finance.yahoo.comIonis to hold third quarter 2023 financial results webcastOctober 7, 2023 | msn.comRBC Capital Reiterates Ionis Pharmaceuticals (IONS) Outperform RecommendationOctober 6, 2023 | markets.businessinsider.comPromising Prospects and Potential Growth: An Analyst’s Buy Rating for Ionis PharmaceuticalsOctober 5, 2023 | markets.businessinsider.comPositive Future Outlook for Ionis Pharmaceuticals: A Comprehensive Analysis of Growth Strategy, Pipeline Developments, and Technological AdvancementsOctober 4, 2023 | finance.yahoo.comIonis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercializationOctober 2, 2023 | msn.comPraxis, Ionis stocks dip in wake of Praxis drug updatesOctober 2, 2023 | finance.yahoo.comPraxis Precision Medicines Provides Portfolio Update at 2023 R&D DaySee More Headlines Receive IONS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today12/06/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IONS CUSIP46433010 CIK874015 Webwww.ionispharma.com Phone(760) 931-9200Fax760-603-2700Employees796Year FoundedN/APrice Target and Rating Average Stock Price Target$48.23 High Stock Price Target$67.00 Low Stock Price Target$27.00 Potential Upside/Downside-3.5%Consensus RatingHold Rating Score (0-4)2.46 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($2.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-269,720,000.00 Net Margins-66.34% Pretax Margin-61.06% Return on Equity-90.50% Return on Assets-14.41% Debt Debt-to-Equity Ratio4.06 Current Ratio6.39 Quick Ratio6.33 Sales & Book Value Annual Sales$587 million Price / Sales12.22 Cash FlowN/A Price / Cash FlowN/A Book Value$4.03 per share Price / Book12.41Miscellaneous Outstanding Shares143,470,000Free Float139,670,000Market Cap$7.17 billion OptionableOptionable Beta0.49 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Brett P. Monia Ph.D. (Age 62)Founder, CEO & Director Comp: $1.71MMs. Elizabeth L. Hougen M.A. (Age 61)M.B.A., M.S., Executive VP of Finance & CFO Comp: $1.02MMs. Onaiza Cadoret-Manier M.A. (Age 58)M.B.A., M.S., Executive VP, Chief Global Product Strategy & Operations Officer Comp: $930.82kMs. B. Lynne Parshall Esq. (Age 69)J.D., Senior Strategic Advisor & Director Comp: $334.64kDr. Richard S. Geary Ph.D. (Age 65)Executive VP & Chief Development Officer Comp: $946.26kMr. Joseph T. Baroldi M.A. (Age 44)M.B.A., M.S., Executive VP & Chief Business Officer Comp: $815.87kMr. Darren GonzalesChief Accounting Officer & Senior VPDr. C. Frank Bennett BSc (Age 66)Ph.D., Executive VP & Chief Scientific Officer Comp: $651.64kMr. D. Wade Walke Ph.D.Senior Vice President of Investor RelationsMr. Patrick R. O'Neil Esq. (Age 49)Executive VP, Chief Legal Officer, General Counsel & Corporate Secretary Comp: $815.69kMore ExecutivesKey CompetitorsJazz PharmaceuticalsNASDAQ:JAZZImmunoGenNASDAQ:IMGNMadrigal PharmaceuticalsNASDAQ:MDGLAlkermesNASDAQ:ALKSAmicus TherapeuticsNASDAQ:FOLDView All CompetitorsInsiders & InstitutionsWellington Management Group LLPBought 845,902 shares on 12/1/2023Ownership: 1.227%American Century Companies Inc.Bought 375 shares on 11/30/2023Ownership: 0.009%Graham Capital Management L.P.Bought 14,488 shares on 11/22/2023Ownership: 0.010%Walleye Capital LLCSold 8,100 shares on 11/21/2023Ownership: 0.000%Walleye Trading LLCBought 5,300 shares on 11/21/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions IONS Stock Analysis - Frequently Asked Questions Should I buy or sell Ionis Pharmaceuticals stock right now? 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 2 sell ratings, 4 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" IONS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IONS, but not buy additional shares or sell existing shares. View IONS analyst ratings or view top-rated stocks. What is Ionis Pharmaceuticals' stock price target for 2024? 13 Wall Street research analysts have issued 1 year price targets for Ionis Pharmaceuticals' shares. Their IONS share price targets range from $27.00 to $67.00. On average, they predict the company's share price to reach $48.23 in the next twelve months. This suggests that the stock has a possible downside of 3.3%. View analysts price targets for IONS or view top-rated stocks among Wall Street analysts. How have IONS shares performed in 2023? Ionis Pharmaceuticals' stock was trading at $37.77 at the beginning of the year. Since then, IONS stock has increased by 32.1% and is now trading at $49.89. View the best growth stocks for 2023 here. When is Ionis Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024. View our IONS earnings forecast. How were Ionis Pharmaceuticals' earnings last quarter? Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) posted its quarterly earnings results on Thursday, November, 2nd. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($1.01) by $0.02. The business earned $144 million during the quarter, compared to analysts' expectations of $139.42 million. Ionis Pharmaceuticals had a negative trailing twelve-month return on equity of 90.50% and a negative net margin of 66.34%. What ETFs hold Ionis Pharmaceuticals' stock? ETFs with the largest weight of Ionis Pharmaceuticals (NASDAQ:IONS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Morningstar US Small Growth (MSGR), First Trust NYSE Arca Biotechnology Index Fund (FBT), Horizon Kinetics Medical ETF (MEDX), Franklin Genomic Advancements ETF (HELX), Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC) and VanEck Morningstar SMID Moat ETF (SMOT). What other stocks do shareholders of Ionis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD). Who are Ionis Pharmaceuticals' major shareholders? Ionis Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (14.98%), Clearbridge Investments LLC (3.37%), Tweedy Browne Co LLC (2.45%), ARK Investment Management LLC (1.65%), Wellington Management Group LLP (1.23%) and Charles Schwab Investment Management Inc. (0.87%). Insiders that own company stock include Allene M Diaz, B Lynne Parshall, Brett P Monia, Brian Birchler, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View institutional ownership trends. How do I buy shares of Ionis Pharmaceuticals? Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:IONS) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.